JP2018506961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506961A5 JP2018506961A5 JP2017532709A JP2017532709A JP2018506961A5 JP 2018506961 A5 JP2018506961 A5 JP 2018506961A5 JP 2017532709 A JP2017532709 A JP 2017532709A JP 2017532709 A JP2017532709 A JP 2017532709A JP 2018506961 A5 JP2018506961 A5 JP 2018506961A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- domain
- axl
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101150022345 GAS6 gene Proteins 0.000 claims 1
- 101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 101150098329 Tyro3 gene Proteins 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000011257 definitive treatment Methods 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 102000045684 human MERTK Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000033300 receptor internalization Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021033363A JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1422605.4 | 2014-12-18 | ||
| GB201422605 | 2014-12-18 | ||
| PCT/EP2015/080654 WO2016097370A2 (en) | 2014-12-18 | 2015-12-18 | Anti-axl antagonistic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021033363A Division JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506961A JP2018506961A (ja) | 2018-03-15 |
| JP2018506961A5 true JP2018506961A5 (enExample) | 2019-01-24 |
| JP6931609B2 JP6931609B2 (ja) | 2021-09-08 |
Family
ID=55080088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532709A Expired - Fee Related JP6931609B2 (ja) | 2014-12-18 | 2015-12-18 | 抗Ａｘｌアンタゴニスト抗体 |
| JP2021033363A Pending JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021033363A Pending JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10208121B2 (enExample) |
| EP (1) | EP3233119A2 (enExample) |
| JP (2) | JP6931609B2 (enExample) |
| KR (1) | KR102453227B1 (enExample) |
| CN (2) | CN107531786B (enExample) |
| AU (1) | AU2015366213B2 (enExample) |
| CA (1) | CA2969879A1 (enExample) |
| MX (1) | MX390849B (enExample) |
| WO (1) | WO2016097370A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| MX390849B (es) * | 2014-12-18 | 2025-03-21 | Bergenbio Asa | Anticuerpos antagonistas anti-axl. |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201509338D0 (en) * | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CN110959014B (zh) * | 2017-07-18 | 2024-01-16 | 协和麒麟株式会社 | 抗人ccr1单克隆抗体 |
| US20210070869A1 (en) * | 2018-04-10 | 2021-03-11 | Genmab A/S | Axl-specific antibodies for cancer treatment |
| CN112639474A (zh) * | 2018-05-14 | 2021-04-09 | 卑尔根生物股份公司 | 血清生物标志物 |
| CN110540592B (zh) | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| CN109206489A (zh) * | 2018-09-29 | 2019-01-15 | 未名生物医药有限公司 | 蛋白序列12g12及其用途 |
| CN109206490A (zh) * | 2018-09-29 | 2019-01-15 | 未名生物医药有限公司 | 蛋白序列11b09及其用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3946453A4 (en) * | 2019-03-29 | 2022-12-07 | Celldex Therapeutics, Inc. | ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
| MY209381A (en) | 2020-02-28 | 2025-07-04 | Servier Lab | Anti-axl antibodies and compositions |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| CN115916344A (zh) | 2020-04-08 | 2023-04-04 | 卑尔根生物股份公司 | 用于抗病毒疗法的axl抑制剂 |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AU2022211971A1 (en) | 2021-01-29 | 2023-08-10 | Illimis Therapeutics, Inc. | Fusion molecule having non-inflammatory phagocytosis inducing activity |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| EP4357365A4 (en) * | 2021-06-16 | 2025-06-04 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibodies against AXL protein and antigen-binding fragment thereof, as well as methods of production and use thereof |
| WO2024197157A1 (en) * | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| JP5769969B2 (ja) * | 2007-11-12 | 2015-08-26 | ユー３・ファーマ・ゲーエムベーハー | Ａｘｌ抗体 |
| EP2228392A4 (en) * | 2007-11-15 | 2012-05-02 | Chugai Pharmaceutical Co Ltd | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO AN UNCONTROLLED GENE (ANEXELEKTO) AND USE THEREOF |
| WO2010130751A1 (en) | 2009-05-11 | 2010-11-18 | U3 Pharma Gmbh | Humanized axl antibodies |
| WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| BR112012027995A2 (pt) * | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| JP5753905B2 (ja) | 2011-05-06 | 2015-07-22 | チョンシャン ホスピタル フダン ユニバーシティ | 血漿ｍｉｃｒｏＲＮＡの組合せからなる肝細胞がん診断マーカーを含む、肝細胞がんの診断キット |
| BR112013032899A2 (pt) * | 2011-06-22 | 2017-01-24 | Inserm Inst Nat De La Santé Et De La Rech Médicale | anticorpos anti-axl e utilizações dos mesmos |
| AU2012273954A1 (en) * | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) * | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| KR102048250B1 (ko) | 2012-06-29 | 2019-11-25 | 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 | 알킬 방향족 탄화수소의 분리방법 및 분리장치 |
| CN104955842B (zh) * | 2012-11-05 | 2018-04-10 | 皮埃尔法布雷医药公司 | 抗原结合蛋白及其作为定位产品用于治疗癌症的用途 |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| US9986723B2 (en) * | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| MX390849B (es) | 2014-12-18 | 2025-03-21 | Bergenbio Asa | Anticuerpos antagonistas anti-axl. |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
-
2015
- 2015-12-18 MX MX2017007941A patent/MX390849B/es unknown
- 2015-12-18 WO PCT/EP2015/080654 patent/WO2016097370A2/en not_active Ceased
- 2015-12-18 EP EP15822930.2A patent/EP3233119A2/en not_active Withdrawn
- 2015-12-18 JP JP2017532709A patent/JP6931609B2/ja not_active Expired - Fee Related
- 2015-12-18 US US15/533,049 patent/US10208121B2/en active Active
- 2015-12-18 AU AU2015366213A patent/AU2015366213B2/en not_active Ceased
- 2015-12-18 CA CA2969879A patent/CA2969879A1/en active Pending
- 2015-12-18 CN CN201580069347.4A patent/CN107531786B/zh not_active Expired - Fee Related
- 2015-12-18 CN CN202211672522.7A patent/CN116410318A/zh active Pending
- 2015-12-18 KR KR1020177018063A patent/KR102453227B1/ko active Active
-
2018
- 2018-12-19 US US16/224,935 patent/US11584796B2/en active Active
-
2021
- 2021-03-03 JP JP2021033363A patent/JP2021101707A/ja active Pending
-
2023
- 2023-02-17 US US18/170,929 patent/US20230406941A1/en active Pending